Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion type Assertion NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_head.
- NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion description "[In this study, we compared the anti-cancer activity of PTX-2 in order to further test the status of p53 using two well-known hepatocarcinoma cell lines, p53-deficient Hep3B and p53-wild-type HepG2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_provenance.
- NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion evidence source_evidence_literature NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_provenance.
- NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion SIO_000772 18202802 NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_provenance.
- NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion wasDerivedFrom befree-2016 NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_provenance.
- NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_assertion wasGeneratedBy ECO_0000203 NP650591.RA1meZ7ZF1sCD0K5XDnfJLzpf7u9yzSJc2zruMSb0_45E130_provenance.